653 Phase I/II clinical trial for radiation and dendritic cell combination immunotherapy in patients with unresectable hepatocellular carcinoma and cholangiocarcinoma
Chen Wu(University of Electronic Science and Technology of China), Lewis R. Roberts(Mayo Clinic), Lin Yi(Mayo Clinic in Arizona), Panwen Wang(Beijing University of Technology), Gabrielle McCoy(Mayo Clinic in Arizona), Nguyen H. Tran(The University of Sydney), Allan B. Dietz(Mayo Clinic), Lionel Aurelien Kankeu Fonkoua(Mayo Clinic in Arizona), Haidong Dong(Mayo Clinic in Arizona), Henan Zhang(Qilu Hospital of Shandong University), Christopher L. Hallemeier(Mayo Clinic in Arizona), Thomas D. Atwell(Mayo Clinic), Svetlana Bornschlegl(Mayo Clinic), Kevin M. Regan(Mayo Clinic in Arizona), Ying Li(The University of Texas at San Antonio Health Science Center), Junwen Wang(National Institutes of Health), Sean S. Park(Mayo Clinic), Zuoyi Shao(Mayo Clinic in Arizona), Kodi Martinez(Mayo Clinic in Arizona)
Cited by 1
Related Papers
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k